Search

Your search keyword '"Jiménez, N."' showing total 22 results
Start Over Author "Jiménez, N." Publisher elsevier ltd
22 results on '"Jiménez, N."'

2. SELNET clinical practice guidelines for soft tissue sarcoma and GIST

Author

Blay, J.Y., Hindi, N., Bollard, J., Aguiar, S., Jr., Angel, M., Araya, B., Badilla, R., Bernabeu, D., Campos, F., Caro-Sánchez, C.H.S., Carvajal, B., Carvajal Montoya, A., Casavilca-Zambrano, S., Castro-Oliden, V., Chacón, M., Clara, M., Collini, P., Correa Genoroso, R., Costa, F.D., Cuellar, M., dei Tos, A.P., Dominguez Malagon, H.R., Donati, D., Dufresne, A., Eriksson, M., Farias-Loza, M., Fernandez, P., Frezza, A.M., Frisoni, T., Garcia-Ortega, D.Y., Gelderblom, H., Gouin, F., Gómez-Mateo, M.C., Gronchi, A., Haro, J., Huanca, L., Jimenez, N., Karanian, M., Kasper, B., Lopes David, B.B., Lopez-Pousa, A., Lutter, G., Martinez-Said, H., Martinez-Tlahuel, J., Mello, C.A., Morales Pérez, J.M., Moura David, S., Nascimento, A.G., Ortiz-Cruz, E.J., Palmerini, E., Patel, S., Pfluger, Y., Provenzano, S., Righi, A., Rodriguez, A., Salas, R., Santos, T.T.G., Scotlandi, K., Soule, T., Stacchiotti, S., Valverde, C., Waisberg, F., Zamora Estrada, E., and Martin-Broto, J.

Published
2022
Full Text
View/download PDF

4. Corrigendum to “SELNET clinical practice guidelines for soft tissue sarcoma and GIST” [Cancer Treat. Rev. 102 (2021) 102312]

Author

Blay, J.Y., Hindi, N., Bollard, J., Aguiar, S., Jr., Angel, M., Araya, B., Badilla, R., Bernabeu, D., Campos, F., Caro-Sánchez, C.H.S., Carvajal, B., Carvajal Montoya, A., Casavilca-Zambrano, S., Castro-Oliden, V., Chacón, M., Clara, M., Collini, P., Correa Genoroso, R., Costa, F.D., Cuellar, M., dei Tos, A.P., Dominguez Malagon, H.R., Donati, D., Dufresne, A., Eriksson, M., Farias-Loza, M., Fernandez, P., Frezza, A.M., Frisoni, T., Garcia-Ortega, D.Y., Gelderblom, H., Gouin, F., Gómez-Mateo, M.C., Gronchi, A., Haro, J., Huanca, L., Jimenez, N., Karanian, M., Kasper, B., Lopes David, B.B., Lopez-Pousa, A., Lutter, G., Martinez-Said, H., Martinez-Tlahuel, J., Mello, C.A., Morales Pérez, J.M., Moura David, S., Nascimento, A.G., Ortiz-Cruz, E.J., Palmerini, E., Patel, S., Pfluger, Y., Provenzano, S., Righi, A., Rodriguez, A., Salas, R., Santos, T.T.G., Scotlandi, K., Soule, T., Stacchiotti, S., Valverde, C., Waisberg, F., Zamora Estrada, E., and Martin-Broto, J.

Published
2023
Full Text
View/download PDF

9. 625P TMPRSS2-ERG expression and clinical evolution of metastatic hormone sensitive prostate cancer

Author

Aversa, C., Jimenez, N., Marín-Aguilera, M., Ferrer, L., Rodríguez-Carunchio, L., Diaz-Mercedes, S., Font Pous, A., Rodriguez-Vida, A., Domenech Santasusana, M., Figols Gorina, M., Climent Duran, M.A., Cros Costa, S., Chirivella, I., Herrero Rivera, D., Gonzalez-Billalabeitia, E., Jiménez-Peralta, D., Carles Galceran, J., Suarez Rodriguez, C., Reig Torras, O., and Mellado, B.

Published
2021
Full Text
View/download PDF

10. 1971P Neuroendocrine (NE) expression profiling in non-castrate tumours is associated with poor therapy benefit and adverse clinical outcome in metastatic castration-resistant prostate cancer (mCRPC) patients

Author

Jimenez, N., Reig, O., Castellano, G., Orrillo, M., Ferrer-Mileo, L., Oberoi, H.K., Pesántez, D., Font, A., Domènech, M., Rodríguez-Vida, A., Carles, J., Suárez, C., Sala-González, N., Rodríguez-Carunchio, L., Díaz, S., Prat, A., Marín-Aguilera, M., and Mellado, B.

Published
2020
Full Text
View/download PDF

14. 1686P - Ability of TMPRSS2-ERG (TE) expression to predict taxane benefit depending on prior abiraterone or enzalutamide therapy in castration-resistant prostate cancer

Author

Marín-Aguilera, M., Reig, O., Font, A., Rodríguez-Vida, A., Suárez, C., Domenech, M., Jiménez, N., Victoria, I., López, S., Milà-Guasch, M., Felip, E., Etxaniz, O., Carles, J., Racca, F., Sala-González, N., González del Alba, A., Fernández, P.L., Prat, A., and Mellado, B.

Published
2017
Full Text
View/download PDF

22. Role of the first WHO mutation catalogue in the diagnosis of antibiotic resistance in Mycobacterium tuberculosis in the Valencia Region, Spain: a retrospective genomic analysis.

Author

García-Marín AM, Cancino-Muñoz I, Torres-Puente M, Villamayor LM, Borrás R, Borrás-Máñez M, Bosque M, Camarena JJ, Colomer-Roig E, Colomina J, Escribano I, Esparcia-Rodríguez O, Gil-Brusola A, Gimeno C, Gimeno-Gascón A, Gomila-Sard B, González-Granda D, Gonzalo-Jiménez N, Guna-Serrano MR, López-Hontangas JL, Martín-González C, Moreno-Muñoz R, Navarro D, Navarro M, Orta N, Pérez E, Prat J, Rodríguez JC, Ruiz-García MM, Vanaclocha H, González-Candelas F, Furió V, and Comas I

Subjects
Humans, Antitubercular Agents pharmacology, Antitubercular Agents therapeutic use, Isoniazid therapeutic use, Rifampin therapeutic use, Microbial Sensitivity Tests, Retrospective Studies, Spain epidemiology, Drug Resistance, Multiple, Bacterial genetics, Mutation genetics, Genomics, World Health Organization, Mycobacterium tuberculosis genetics, Tuberculosis, Multidrug-Resistant diagnosis, Tuberculosis, Multidrug-Resistant drug therapy, Tuberculosis, Multidrug-Resistant microbiology
Abstract

Background: In June, 2021, WHO published the most complete catalogue to date of resistance-conferring mutations in Mycobacterium tuberculosis. Here, we aimed to assess the performance of genome-based antimicrobial resistance prediction using the catalogue and its potential for improving diagnostics in a real low-burden setting., Methods: In this retrospective population-based genomic study M tuberculosis isolates were collected from 25 clinical laboratories in the low-burden setting of the Valencia Region, Spain. Culture-positive tuberculosis cases reported by regional public health authorities between Jan 1, 2014, and Dec 31, 2016, were included. The drug resistance profiles of these isolates were predicted by the genomic identification, via whole-genome sequencing (WGS), of the high-confidence resistance-causing variants included in the catalogue and compared with the phenotype. We determined the minimum inhibitory concentration (MIC) of the isolates with discordant resistance profiles using the resazurin microtitre assay., Findings: WGS was performed on 785 M tuberculosis complex culture-positive isolates, and the WGS resistance prediction sensitivities were: 85·4% (95% CI 70·8-94·4) for isoniazid, 73·3% (44·9-92·2) for rifampicin, 50·0% (21·1-78·9) for ethambutol, and 57·1% (34·0-78·2) for pyrazinamide; all specificities were more than 99·6%. Sensitivity values were lower than previously reported, but the overall pan-susceptibility accuracy was 96·4%. Genotypic analysis revealed that four phenotypically susceptible isolates carried mutations (rpoB Leu430Pro and rpoB Ile491Phe for rifampicin and fabG1 Leu203Leu for isoniazid) known to give borderline resistance in standard phenotypic tests. Additionally, we identified three putative resistance-associated mutations (inhA Ser94Ala, katG Leu48Pro, and katG Gly273Arg for isoniazid) in samples with substantially higher MICs than those of susceptible isolates. Combining both genomic and phenotypic data, in accordance with the WHO diagnostic guidelines, we could detect two new multidrug-resistant cases. Additionally, we detected 11 (1·6%) of 706 isolates to be monoresistant to fluoroquinolone, which had been previously undetected., Interpretation: We showed that the WHO catalogue enables the detection of resistant cases missed in phenotypic testing in a low-burden region, thus allowing for better patient-tailored treatment. We also identified mutations not included in the catalogue, relevant at the local level. Evidence from this study, together with future updates of the catalogue, will probably lead in the future to the partial replacement of culture testing with WGS-based drug susceptibility testing in our setting., Funding: European Research Council and the Spanish Ministerio de Ciencia., Competing Interests: Declaration of interests IC received consultancy fees from the Foundation for Innovative New Diagnostics. IC and VF have participated in the elaboration of the WHO catalogue used in this study. All other authors declare no competing interests., (Copyright © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results